What Do COVID-19 Vaccines Tell Us About Nucleic Acid Delivery In Vivo?
The utilization of the m RNA-based Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccines represents the culmination of many years of nonviral nucleic acid delivery, but more importantly, they signify a massive clinical scientific success . Scientists working in the area of nucleic...
Gespeichert in:
Veröffentlicht in: | Nucleic acid therapeutics 2021-10, Vol.31 (5), p.321-323 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The utilization of the
m
RNA-based Pfizer-BioNTech and Moderna coronavirus disease 2019 (COVID-19) vaccines represents the culmination of many years of nonviral nucleic acid delivery, but more importantly, they signify a massive clinical
scientific success
. Scientists working in the area of nucleic acid delivery using lipid nanoparticles will undoubtedly be energized by the success of these vaccines and begin to collect much needed data in the realm of nonviral-based RNA
and DNA
delivery, specifically, the use of lipid nanoparticles, the immune response, safety, and efficacy. It is easily conceivable that in the future we can utilize these data to
help
streamline our approach for the delivery of
DNA
for gene therapy and
regulatory RNAs for
therapeutic and regenerative medicine (ie, wound repair) applications
. |
---|---|
ISSN: | 2159-3337 2159-3345 |
DOI: | 10.1089/nat.2021.0013 |